[Cost of low molecular weight heparin used in the prevention or therapy of thromboembolic disease].
Low-molecular-weight heparin are widely used for prophylaxis or curative treatment of thromboembolic disease. In France, low molecular weight heparin can only be used for the surgical prophylaxis (general and orthopaedic) of thromboembolic disease, for the initial treatment of deep vein thrombosis and in haemodialysis. In an economic approach we try to assess costing information which takes account of drug acquisition costs but also costs of drug administration and costs of drug therapy failure (failed prophylaxis, bleeding and recurrent thrombosis). At least, it has been argued that low molecular weight heparin may take it possible to discharge patients earlier and even to treat patients at home or as out-patients, thus creating further cost savings.
Lévesque
H
H
Département de médecine interne, CHU Rouen-Boisguillaume, France.
Marie
I
I
Cailleux
N
N
Hantute
N
N
Courtois
H
H
D003363:Cost Control; D003362:Cost-Benefit Analysis; D005602:France; D006495:Heparin, Low-Molecular-Weight / Q000191:economics*; D006801:Humans; D013923:Thromboembolism / Q000191:economics* / Q000517:prevention & control / Q000628:therapy
D006495:Heparin, Low-Molecular-Weight
Coût des héparines de bas poids moléculaire utilisées en prophylaxie ou en traitement curatif de la maladie thromboembolique.